Salivary SARS-CoV-2 Load of Covid-19 Patients After Oral Antimicrobial Solutions and Dentifrices

Summary

The aim of this study is to analyze if the use of oral antimicrobial solutions and dentifricies are able to reduce the SARS-CoV-2 load in the saliva and oral mucosa. It will be allocated hospitalized patients positive for SARS-CoV-2 (confirmed by RT-PCR of nasopharynx swab tests) and with signs and symptoms of COVID-19. These patients will be divided into two groups: patients enrolled in negative pressure rooms (NPR), and patients enrolled in intensive care units (ICU) with orotracheal intubation. These two groups will receive interventions with oral antimicrobial solutions or dentifrices, containing different compounds. Saliva and oral mucosa swabs will be collected before the intervention, immediately after the intervention, and after 30min and 1h. The primary outcome is to verify if these products can reduce the SARS-CoV-2 load in the saliva and oral mucosa at these time periods, detected by the measurement of the viral load and the fold-reduction.

Conditions

• Corona Virus Infection

Interventions

OTHER

Colgate Periogard® mouthwash

Patients will be submitted to antisepsia of the oral mucosa with Colgate Periogard® mouthwash

OTHER

Colgate Peroxyl® mouthwash

Patients will be submitted to antisepsia of the oral mucosa with Colgate Peroxyl® mouthwash

OTHER

Colgate Total® Mouthwash

Patients will be submitted to antisepsia of the oral mucosa with Colgate Total® Mouthwash

OTHER

Toothpaste with sodium monofluorophosphate

Patients will be submitted to brushing with toothpaste with sodium monofluorophosphate

OTHER

Toothpaste with sodium fluoride and zinc

Patients will be submitted to brushing with toothpaste with sodium fluoride and zinc

OTHER

Toothpaste with tin fluoride

Patients will be submitted to brushing with toothpaste with tin fluoride

Sponsors & Collaborators

• Colgate Palmolive

  collaborator INDUSTRY

• Hospital Israelita Albert Einstein

  lead OTHER

Principal Investigators

• Luciana Correa, PhD · University of Sao Paulo

• Debora H Douek, PhD · Hospital Israelita Albert Einstein

Study Design

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

TRIPLE

Model

FACTORIAL

Eligibility

Min Age

18 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-07-14

Primary Completion

2020-12-30

Completion

2021-09-30

Countries

• Brazil

Study Locations